Article Figures & Data
Figures
- Fig. 1.
Immunohistochemical staining of human glioma tissue sections demonstrating p-STAT3 and CD3+ lymphoid cells. The p-STAT3 staining was confined to the nucleus, whereas CD3 staining was noted on the cell surface. A, the number of p-STAT3–expressing cells was more evident in astrocytic, higher-grade gliomas. B, CD3 staining showed high numbers of infiltrative CD3+ T cells, also within higher-glioma grades. All images were taken at a magnification of ×400. Normal brain (a), low-grade astrocytoma (b), AA (c), GBM multiforme (d), oligodendroglioma (e), MOA (f), AO (g), and AMOA (h).
- Fig. 2.
Pair-wise scatter plots between p-STAT3, CD3, and CD8 across all tumor pathologies and tumor grades with Loess smooth curves added. The almost straight trend of the Loess curves indicates that both CD3 and CD8 had a strong linear correlation with p-STAT3 expression. Specifically, the correlation of the number of p-STAT3 expressing cells with the number of tumor infiltrating CD3+ T cells was 0.99 (P < 0.001) and with the number of tumor infiltrating CD8+ T cells was 0.94 (P < 0.001).
- Fig. 3.
Kaplan-Meier survival estimates stratified by the presence or absence of p-STAT3 immunohistochemical staining within all patients with gliomas, patients with GBM, and patients with AA. A, among all patients with gliomas without p-STAT3 expression, the median survival time was 34.6 mo (95% CI, 19.2, mo to NA) and 20.1 mo (95% CI, 13.8-43.0 mo) in patients with gliomas with p-STAT3 expression (P = 0.16). B, in patients with GBM multiforme without p-STAT3 expression, the median survival time was 18.1 mo (95% CI, 6.6-41.8 mo) and 10.7 mo (95% CI, 7.5-15.0 mo) in patients with GBM multiforme with p-STAT3 expression (P = 0.12). C, in patients with AA patients without p-STAT3 expression, the median survival time was 34.6 mo (95% CI, 33.9 mo to NA) and 12.2 mo (95% CI, 6.2 mo to NA) in patients with AA with p-STAT3 expression (P = 0.02).
Tables
- Table 1.
Demographic characteristics of patients with glioma stratified according to pathology
Pathology Age (y) KPS Median survival time (mo)* Median Minimum Maximum Median Minimum Maximum O 38.5 7.0 55.0 100 80 100 99.8 MOA 42.5 24.0 52.0 100 70 100 —† AO 40.0 25.0 59.0 90 70 100 —† AMOA 35.5 22.0 47.0 100 80 100 89.2 LGA 33.0 4.0 44.0 95 90 100 166.7 AA 49.0 24.0 91.0 90 90 100 27.7 GS 51.0 23.0 68.0 80 60 100 4.4 GBM 56.0 17.0 77.0 90 50 100 13.8 - Table 2.
Composition of the glioma TMA
Lineage Pathology No. of patients (%) Oligodendroglial (n = 49) O 16 (12.4%) MOA 6 (4.7%) AO 15 (11.6%) AMOA 12 (9.3%) Astrocytic (n = 80) LGA 3 (2.3%) AA 17 (13.2%) GS 7 (5.4%) GBM 53 (41.1%) - Table 3.
Proportion of p-STAT3–positive cases according to pathology and WHO tumor grade
Pathology p-STAT3 >0/total (%) Mean (SD)* (Minimum, maximum) O 6/16 (38%) 4.3 (7.7) (0.0, 23.5) MOA 6/6 (100%) 67.9 (55.2) (9.0, 136.0) AO 6/15 (40%) 17.5 (41.0) (0.0,153.0) AMOA 7/12 (58%) 13.3 (27.0) (0.0, 85.5) LGA 0/3 (0%) 0 0 AA 9/17 (53%) 5.6 (7.6) (0.0, 23.0) GS 5/7 (71%) 23.1 (34.1) (0.0, 91.0) GBM 27/53 (51%) 11.7 (24.4) (0.0, 133.5) ↵* The mean calculation was based on the mean p-STAT3 value.
Volume 14, Issue 24
